The use of pramipexole in Parkinson's disease: Are its actions D3 mediated?

Parkinsonism and Related Disorders

Volumn 7, Issue 3, 2001, Pages 231-234

  Guttman, M ^a   Jaskolka, J ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

D3 dopamine receptor; Parkinson's disease; Pramipexole

Indexed keywords

BROMOCRIPTINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; PERGOLIDE; PLACEBO; PRAMIPEXOLE; ROPINIROLE;

CONFERENCE PAPER; CONSTIPATION; DEPRESSION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; HALLUCINATION; HUMAN; LOCOMOTION; MOOD; NAUSEA; ON OFF PHENOMENON; PARKINSON DISEASE; PRIORITY JOURNAL; SOMNOLENCE;

EID: 0035040790     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(00)00062-6     Document Type: Conference Paper

References (26)

1. Parkinson's disease: first of two parts
2. Parkinson's disease: second of two parts
3. Treatment of Parkinson's disease
4. Drug treatment of Parkinson's disease
5. Bromocriptine in Parkinson's disease
6. A multicenter double-blind placebo controlled trial of pergolide as an adjunct to sinemet in Parkinson's disease
7. Lisuride pharmacology and treatment of Parkinson's disease
8. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease
9. Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations
10. 2 receptor agonist
11. 4 receptors
12. Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans
13. For the pramipexole study group. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease
14. For the Parkinson study group. Safety and efficacy of pramipexole in early Parkinson's disease
15. Pramipexole study group. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study
16. International pramipexole-bromocriptine study group. Double blind comparison of pramipexole and bromocriptine treatment with placebo in advanced parkinson's disease
17. Long-term improvement of wearing off in Parkinson's disease (PD) with pramipexole
18. 3 dopamine receptor: neurobiology and potential clinical relevance
19. 3 dopamine receptor in cellular and organismal function
20. 2 receptor
21. 3 receptor expression as a mechanism of behavioral sensitization to levodopa
22. 2 receptor is elevated in the striatum of Parkinson's disease
23. 2 dopamine receptors in Parkinson's disease striatum
24. 2 receptor density remains constant in treated Parkinson's disease
25. 3 receptor agonists: Combined action neurological and neuropsychiatric agents
26. Pramipexole, a dopamine agonist in major depression: antidepressant effects and tolerability in an open label study with multiple doses